{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:51:16Z","timestamp":1740163876867,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100017266","name":"Gobierno de Navarra","doi-asserted-by":"publisher","award":["64\/2019"],"award-info":[{"award-number":["64\/2019"]}],"id":[{"id":"10.13039\/501100017266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00415"],"award-info":[{"award-number":["PI20\/00415"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A promising therapy for patients with B-cell lymphoma is based on vaccination with idiotype monoclonal antibodies (mAbs). Since idiotypes are different in each tumor, a personalized vaccine has to be produced for each patient. Expression of immunoglobulins with appropriate post-translational modifications for human use often requires the use of stable mammalian cells that can be scaled-up to reach the desired level of production. We have used a noncytopathic self-amplifying RNA vector derived from Semliki Forest virus (ncSFV) to generate BHK cell lines expressing murine follicular lymphoma-derived idiotype A20 mAb. ncSFV\/BHK cell lines expressed approximately 2\u00a0mg\/L\/24\u00a0h of A20 mAb with proper quaternary structure and a glycosylation pattern similar to that of A20 mAb produced by hybridoma cells. A20 mAb purified from the supernatant of a ncSFV cell line, or from the hybridoma, was conjugated to keyhole limpet hemocyanin and used to immunize Balb\/c mice by administration of four weekly doses of 25\u00a0\u00b5g of mAb. Both idiotype mAbs were able to induce a similar antitumor protection and longer survival compared to non-immunized mice. These results indicate that the ncSFV RNA vector could represent a quick and efficient system to produce patient-specific idiotypes with potential application as lymphoma vaccines.<\/jats:p>","DOI":"10.1038\/s41598-021-00787-5","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T11:03:37Z","timestamp":1635851017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Erkuden","family":"Casales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Martisova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ascensi\u00f3n L\u00f3pez D\u00edaz","family":"de Cerio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Inoges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelia","family":"Silva-Pilipich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Cristina","family":"Ballesteros-Briones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Aranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaione","family":"Bezunartea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Bendandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Smerdou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"key":"787_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1365-2141.2008.07143.x","volume":"142","author":"HJ Park","year":"2008","unstructured":"Park, H. J. & Neelapu, S. S. Developing idiotype vaccines for lymphoma: From preclinical studies to phase III clinical trials. Br. J. Haematol. 142, 179\u2013191. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07143.x (2008).","journal-title":"Br. J. Haematol."},{"key":"787_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2217\/imt-2016-0080","volume":"8","author":"TU Marron","year":"2016","unstructured":"Marron, T. U., Ronner, L., Martin, P. E., Flowers, C. R. & Brody, J. D. Vaccine strategies for the treatment of lymphoma: Preclinical progress and clinical trial update. Immunotherapy 8, 1335\u20131346. https:\/\/doi.org\/10.2217\/imt-2016-0080 (2016).","journal-title":"Immunotherapy"},{"key":"787_CR3","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1182\/blood.v65.6.1349.bloodjournal6561349","volume":"65","author":"TC Meeker","year":"1985","unstructured":"Meeker, T. C. et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65, 1349\u20131363. https:\/\/doi.org\/10.1182\/blood.v65.6.1349.bloodjournal6561349 (1985).","journal-title":"Blood"},{"key":"787_CR4","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1182\/blood.v80.6.1502.bloodjournal8061502","volume":"80","author":"DG Maloney","year":"1992","unstructured":"Maloney, D. G. et al. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 80, 1502\u20131510. https:\/\/doi.org\/10.1182\/blood.v80.6.1502.bloodjournal8061502 (1992).","journal-title":"Blood"},{"key":"787_CR5","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3389\/fimmu.2019.00808","volume":"10","author":"H Kohler","year":"2019","unstructured":"Kohler, H., Pashov, A. & Kieber-Emmons, T. The promise of anti-idiotype revisited. Front. Immunol. 10, 808. https:\/\/doi.org\/10.3389\/fimmu.2019.00808 (2019).","journal-title":"Front. Immunol."},{"key":"787_CR6","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1182\/blood.V97.5.1370","volume":"97","author":"JM Timmerman","year":"2001","unstructured":"Timmerman, J. M., Caspar, C. B., Lambert, S. L., Syrengelas, A. D. & Levy, R. Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood 97, 1370\u20131377. https:\/\/doi.org\/10.1182\/blood.V97.5.1370 (2001).","journal-title":"Blood"},{"key":"787_CR7","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.4049\/jimmunol.168.8.3983","volume":"168","author":"AC Armstrong","year":"2002","unstructured":"Armstrong, A. C. et al. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: Induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J. Immunol. 168, 3983\u20133991. https:\/\/doi.org\/10.4049\/jimmunol.168.8.3983 (2002).","journal-title":"J. Immunol."},{"key":"787_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nrc2717","volume":"9","author":"M Bendandi","year":"2009","unstructured":"Bendandi, M. Idiotype vaccines for lymphoma: Proof-of-principles and clinical trial failures. Nat. Rev. Cancer 9, 675\u2013681. https:\/\/doi.org\/10.1038\/nrc2717 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"787_CR9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1586\/erv.11.44","volume":"10","author":"S Inog\u00e9s","year":"2011","unstructured":"Inog\u00e9s, S. et al. Idiotype vaccines for lymphoma therapy. Expert Rev. Vaccines 10, 801\u2013809. https:\/\/doi.org\/10.1586\/erv.11.44 (2011).","journal-title":"Expert Rev. Vaccines"},{"doi-asserted-by":"crossref","unstructured":"Lundstrom, K. Alphavirus-based antigen preparation. In Methods in Molecular Biology 63\u201381 (2021).","key":"787_CR10","DOI":"10.1007\/978-1-0716-0795-4_6"},{"key":"787_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1525-0016(02)00056-4","volume":"7","author":"K Lundstrom","year":"2003","unstructured":"Lundstrom, K., Abenavoli, A., Malgaroli, A. & Ehrengruber, M. U. Novel Semliki Forest virus vectors with reduced cytotoxicity and temperature sensitivity for long-term enhancement of transgene expression. Mol. Ther. 7, 202\u2013209. https:\/\/doi.org\/10.1016\/S1525-0016(02)00056-4 (2003).","journal-title":"Mol. Ther."},{"key":"787_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.2174\/187220811797579060","volume":"5","author":"A Aranda","year":"2011","unstructured":"Aranda, A. et al. Recent patents on alphavirus protein expression and vector production. Recent Pat. Biotechnol. 5, 212\u2013226. https:\/\/doi.org\/10.2174\/187220811797579060 (2011).","journal-title":"Recent Pat. Biotechnol."},{"key":"787_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.virol.2008.03.016","volume":"376","author":"E Casales","year":"2008","unstructured":"Casales, E. et al. Development of a new noncytopathic Semliki Forest virus vector providing high expression levels and stability. Virology 376, 242\u2013251. https:\/\/doi.org\/10.1016\/j.virol.2008.03.016 (2008).","journal-title":"Virology"},{"key":"787_CR14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.nbt.2010.02.005","volume":"27","author":"E Casales","year":"2010","unstructured":"Casales, E. et al. A novel system for the production of high levels of functional human therapeutic proteins in stable cells with a Semliki Forest virus noncytopathic vector. N. Biotechnol. 27, 138\u2013148. https:\/\/doi.org\/10.1016\/j.nbt.2010.02.005 (2010).","journal-title":"N. Biotechnol."},{"key":"787_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/978-1-4939-0345-0_30","volume":"1139","author":"S Inoges","year":"2014","unstructured":"Inoges, S., D\u00edaz de Cerio, A. L., Villanueva, H., Pastor, F. & Bendandi, M. Idiotype vaccine production using hybridoma technology. Methods Mol. Biol. 1139, 367\u2013387. https:\/\/doi.org\/10.1007\/978-1-4939-0345-0_30 (2014).","journal-title":"Methods Mol. Biol."},{"key":"787_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ymthe.2005.02.011","volume":"12","author":"JR Rodriguez-Madoz","year":"2005","unstructured":"Rodriguez-Madoz, J. R., Prieto, J. & Smerdou, C. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol. Ther. 12, 153\u2013163. https:\/\/doi.org\/10.1016\/j.ymthe.2005.02.011 (2005).","journal-title":"Mol. Ther."},{"key":"787_CR17","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1038\/nbt1291-1356","volume":"9","author":"P Liljestr\u00f6m","year":"1991","unstructured":"Liljestr\u00f6m, P. & Garoff, H. A new generation of animal cell expression vectors based on the semliki forest virus replicon. Bio\/Technology 9, 1356\u20131361. https:\/\/doi.org\/10.1038\/nbt1291-1356 (1991).","journal-title":"Bio\/Technology"},{"key":"787_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jbiotec.2013.03.019","volume":"165","author":"SCL Ho","year":"2013","unstructured":"Ho, S. C. L. et al. Control of IgG LC: HC ratio in stably transfected CHO cells and study of the impact on expression, aggregation, glycosylation and conformational stability. J. Biotechnol. 165, 157\u2013166. https:\/\/doi.org\/10.1016\/j.jbiotec.2013.03.019 (2013).","journal-title":"J. Biotechnol."},{"key":"787_CR19","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","volume":"29","author":"CS Shemesh","year":"2021","unstructured":"Shemesh, C. S. et al. Personalized cancer vaccines: Clinical landscape, challenges, and opportunities. Mol. Ther. 29, 555\u2013570. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.038 (2021).","journal-title":"Mol. Ther."},{"key":"787_CR20","first-page":"373","volume":"125C","author":"NK Jerne","year":"1974","unstructured":"Jerne, N. K. Towards a network theory of the immune system. Ann. Immunol. 125C, 373\u2013389 (1974).","journal-title":"Ann. Immunol."},{"key":"787_CR21","doi-asserted-by":"publisher","first-page":"6625","DOI":"10.4049\/jimmunol.181.9.6625","volume":"181","author":"AM Hern\u00e1ndez","year":"2008","unstructured":"Hern\u00e1ndez, A. M. et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J. Immunol. 181, 6625\u20136634. https:\/\/doi.org\/10.4049\/jimmunol.181.9.6625 (2008).","journal-title":"J. Immunol."},{"key":"787_CR22","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/nbt1026","volume":"22","author":"FM Wurm","year":"2004","unstructured":"Wurm, F. M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22, 1393\u20131398. https:\/\/doi.org\/10.1038\/nbt1026 (2004).","journal-title":"Nat. Biotechnol."},{"key":"787_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/protein\/gzm038","volume":"20","author":"J Li","year":"2007","unstructured":"Li, J., Zhang, C., Jostock, T. & D\u00fcbel, S. Analysis of IgG heavy chain to light chain ratio with mutant Encephalomyocarditis virus internal ribosome entry site. Protein Eng. Des. Sel. 20, 491\u2013496. https:\/\/doi.org\/10.1093\/protein\/gzm038 (2007).","journal-title":"Protein Eng. Des. Sel."},{"key":"787_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.tibtech.2005.12.006","volume":"24","author":"P De Felipe","year":"2006","unstructured":"De Felipe, P. et al. E unum pluribus: Multiple proteins from a self-processing polyprotein. Trends Biotechnol. 24, 68\u201375. https:\/\/doi.org\/10.1016\/j.tibtech.2005.12.006 (2006).","journal-title":"Trends Biotechnol."},{"key":"787_CR25","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ymthe.2019.09.016","volume":"27","author":"MC Ballesteros-Briones","year":"2019","unstructured":"Ballesteros-Briones, M. C. et al. Short-term local expression of a PD-L1 blocking antibody from a self-replicating RNA vector induces potent antitumor responses. Mol. Ther. 27, 1892\u20131905. https:\/\/doi.org\/10.1016\/j.ymthe.2019.09.016 (2019).","journal-title":"Mol. Ther."},{"key":"787_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biologicals.2017.11.001","volume":"52","author":"F Cymer","year":"2018","unstructured":"Cymer, F., Beck, H., Rohde, A. & Reusch, D. Therapeutic monoclonal antibody N-glycosylation\u2014Structure, function and therapeutic potential. Biologicals 52, 1\u201311. https:\/\/doi.org\/10.1016\/j.biologicals.2017.11.001 (2018).","journal-title":"Biologicals"},{"key":"787_CR27","doi-asserted-by":"publisher","first-page":"5503","DOI":"10.2174\/1381612811319310006","volume":"19","author":"D Bosch","year":"2013","unstructured":"Bosch, D., Castilho, A., Loos, A., Schots, A. & Steinkellner, H. N-Glycosylation of plant-produced recombinant proteins. Curr. Pharm. Des. 19, 5503\u20135512. https:\/\/doi.org\/10.2174\/1381612811319310006 (2013).","journal-title":"Curr. Pharm. Des."},{"key":"787_CR28","doi-asserted-by":"publisher","first-page":"648143","DOI":"10.1155\/2015\/648143","volume":"2015","author":"D Tus\u00e9","year":"2015","unstructured":"Tus\u00e9, D. et al. Clinical safety and Immunogenicity of tumor-targeted, plant-made id-klh conjugate vaccines for follicular lymphoma. Biomed Res. Int. 2015, 648143. https:\/\/doi.org\/10.1155\/2015\/648143 (2015).","journal-title":"Biomed Res. Int."},{"key":"787_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2017.1285477","volume":"13","author":"AN Meleshko","year":"2017","unstructured":"Meleshko, A. N. et al. Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma. Hum. Vaccines Immunother. 13, 1\u20136. https:\/\/doi.org\/10.1080\/21645515.2017.1285477 (2017).","journal-title":"Hum. Vaccines Immunother."},{"key":"787_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12885-018-4094-2","volume":"18","author":"SK Thomas","year":"2018","unstructured":"Thomas, S. K. et al. Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: Study protocol. BMC Cancer 18, 187. https:\/\/doi.org\/10.1186\/s12885-018-4094-2 (2018).","journal-title":"BMC Cancer"},{"key":"787_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.coviro.2020.08.003","volume":"44","author":"MC Ballesteros-Briones","year":"2020","unstructured":"Ballesteros-Briones, M. C., Silva-Pilipich, N., Herrador-Ca\u00f1ete, G., Vanrell, L. & Smerdou, C. A new generation of vaccines based on alphavirus self-amplifying RNA. Curr. Opin. Virol. 44, 145\u2013153. https:\/\/doi.org\/10.1016\/j.coviro.2020.08.003 (2020).","journal-title":"Curr. Opin. Virol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00787-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00787-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00787-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:56:44Z","timestamp":1670086604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-00787-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["787"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-00787-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2021,11,2]]},"assertion":[{"value":"21 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21427"}}